Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38870977

Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Gastroenterol Hepatol
Publication date
2024 Aug
First author
Vogel A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Gastroenterol Hepatol. 2024 Aug;9(8):683-684. doi: 10.1016/S2468-1253(24)00151-1.
    note
    Source null
    related pmid
    38870978
    relationship
    Comment in

Authors and identifiers

  1. name
    Vogel A
    type
    Author
  2. name
    Saborowski A
    type
    Author
  3. name
    Wenzel P
    type
    Author
  4. name
    Wege H
    type
    Author
  5. name
    Folprecht G
    type
    Author
  6. name
    Kretzschmar A
    type
    Author
  7. name
    Schütt P
    type
    Author
  8. name
    Jacobasch L
    type
    Author
  9. name
    Ziegenhagen N
    type
    Author
  10. name
    Boeck S
    type
    Author
  11. name
    Zhang D
    type
    Author
  12. name
    Kanzler S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Vogel A
    type
    Author
  2. name
    Saborowski A
    type
    Author
  3. name
    Wenzel P
    type
    Author
  4. name
    Wege H
    type
    Author
  5. name
    Folprecht G
    type
    Author
  6. name
    Kretzschmar A
    type
    Author
  7. name
    Schütt P
    type
    Author
  8. name
    Jacobasch L
    type
    Author
  9. name
    Ziegenhagen N
    type
    Author
  10. name
    Boeck S
    type
    Author
  11. name
    Zhang D
    type
    Author
  12. name
    Kanzler S
    type
    Author
bibliography ids
  1. nci-bib-2bf2850196c8b0e6b292adb2
book metadata
content sha256
b494e41835697afa330230f72579844a3a3916e134f5cf2a5baaeafc0e18b4f0
document type
citation
dois
  1. 10.1016/S2468-1253(24)00119-5
electronic publication date
display
2024 Jun 10
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38870977
immutable id
pubmed:38870977@b494e41835697afa330230f72579844a3a3916e134f5cf2a5baaeafc0e18b4f0
journal
abbreviation
Lancet Gastroenterol Hepatol
issn electronic
2468-1253
issn print
Source null
issue
8
name
The lancet. Gastroenterology & hepatology
nlm unique id
101690683
pages
734-744
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Gastroenterol Hepatol. 2024 Aug;9(8):683-684. doi: 10.1016/S2468-1253(24)00151-1.
    note
    Source null
    related pmid
    38870978
    relationship
    Comment in
outcomes validated
false
pmid
38870977
provenance
batch id
3e43afde6f26fc8df6da
provider
NCBI PubMed ESummary
record sha256
b1a732cfe9ecb35acf785f377892feacad46fea1348b95fc3cc9716bc055852a
response sha256
fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
retrieved at
2026-09-09T23:48:21.145285+00:00
publication date
display
2024 Aug
precision
month
year
2024
publication types
  1. Journal Article
  2. Multicenter Study
  3. Clinical Trial, Phase II
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38870977/
title
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.

Preserved source evidence · Not medical advice